Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
about
Role of endoglin in fibrosis and sclerodermaDigital ulcers in systemic sclerosisEndoglin in liver fibrogenesis: Bridging basic science and clinical practiceCorrelations between angiogenic factors and capillaroscopic patterns in systemic sclerosis.Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressureTargeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.The current state of biomarkers in systemic sclerosisEndoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts.Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertensionAsymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.Genistein protects dermal fibrosis in bleomycin-induced experimental sclerodermaSerum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis.The Role of TGF-β Receptors in Fibrosis.The association between systemic sclerosis, arginine and asymmetric dimethylarginine.Biomarkers in systemic sclerosis: Their potential to predict clinical courses.Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.Genetic, metabolic and endocrine aspect of intrauterine growth restriction: an update.An update on biomarker discovery and use in systemic sclerosis.Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis.Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women.Clinical significance of soluble-endoglin levels in systemic lupus erythematosus: possible association with anti-phospholipid syndrome.Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases.Association of hypoxia-inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population.Microvascular involvement in Systemic Sclerosis and Systemic Lupus Erythematosus.Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis.Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis
P2860
Q26821836-453C94C8-2A62-41FE-B4E5-9EF4F0EEA4FAQ28080196-EB5C3C34-B812-4F3F-B9ED-9B77746D5BCDQ33728841-44CCE015-6A32-4084-8889-FA9C57CB3C63Q33765564-D8EDAF87-D32A-450A-BBD2-982485D4B03AQ34143652-7E49825B-2B86-4781-879C-7DF167808394Q34452035-172B7D51-EF8D-425C-8C50-F36C22C8E2F5Q35896754-4812E1B9-1823-46AB-B25A-A2F7590B57AEQ36054237-8E994ABF-3E49-4C18-91E4-ADC0A62A4EA0Q36165049-A83155B8-03B3-400E-BBB4-5EC4A4695047Q36396428-85D48F89-B07E-4B80-81BD-3BC1245372DCQ37224668-59CBACAE-2A2D-48C3-A61F-E791AB5440F9Q37305174-E609088E-4282-4713-A3CF-5CB414E81D5EQ37471750-8DE73EE8-29C6-4192-B716-F532851C8B80Q38026846-69821A21-12D3-4B7E-AAC0-426AAB8CB65AQ38254026-33D4CB9F-54DB-4C62-933B-18AECBFE8B00Q38701985-C73D2B70-3350-4C8F-A6E1-26A9C842F108Q38771824-4953406A-6FED-40D5-B805-098101129C36Q38975741-F00BE64D-E79C-4976-BD3E-876FCC31B4A4Q39450087-23C6207F-0397-4E81-A751-71B8D9FCD6F7Q40355666-92FB50A3-6573-49D2-876A-66B038AD84F4Q43460992-0A56163B-DE22-4C20-A3E3-FC4FCB7054B6Q43600447-BE56F3CA-A64D-453B-BDAF-E20A001DE7BBQ43735034-6BDF8470-B64E-43CC-9CC7-5A71C5140022Q46660838-65541AD3-7D9D-45A5-9DE4-608DDFD2671BQ47660081-B1D13245-CFBC-40D4-8CD2-6FDA7B6B85C3Q54599837-EF7E2A62-9DAC-4789-BD71-C670FEDC0619Q56977476-32887C71-C8BD-4F08-8609-074CD0CA3B03
P2860
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
@en
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
@nl
type
label
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
@en
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
@nl
prefLabel
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
@en
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
@nl
P2093
P356
P1433
P1476
Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin
@en
P2093
P304
P356
10.1093/RHEUMATOLOGY/KEN100
P577
2008-05-13T00:00:00Z